Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD 0328

Known as: AZD-0328, AZD0328 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundThe treatment of Parkinson’s disease is often complicated by levodopa-induced dyskinesia (LID). Nicotinic acetylcholine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Apatinib is a new oral antiangiogenic molecule that inhibits vascular endothelial growth factor receptor-2. The present study… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 3
Is this relevant?
2012
2012
Neuronal nicotinic acetylcholine receptor (nAChR) agonists active at the alpha-7 (α-7) receptor subtype are potential… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Nicotine improves cognition in humans and animal models of neuropsychiatric disorders. Here, we sought to establish… Expand
Is this relevant?
2011
2011
Αlpha-7 neuronal nicotinic receptors (NNRs) are considered targets for cognitive enhancement in schizophrenia and Alzheimer's… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
AZD0328 was pharmacologically characterized as a α7 neuronal nicotinic receptor agonist intended for treatment of Alzheimer′s… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
AZD0328, a novel spirofuropyridine neuronal nicotinic receptor partial agonist, was used to investigate the role of alpha7… Expand
Is this relevant?